How Long Is Monkeypox (Mpox) Contagious?

Most people with mpox are contagious for roughly two to four weeks after symptoms appear, though the infectious window can start before any rash shows up and, in some cases, stretch considerably longer. The answer depends on which body site you’re measuring, whether the person is immunocompromised, and whether you define “contagious” by the presence of live virus or just detectable viral DNA. That distinction matters more than most guidance acknowledges, and it shapes everything from how long you need to isolate to when it’s safe to resume intimate contact.

Contagiousness Can Start Before You Know You’re Sick

Mpox doesn’t wait for visible lesions to become transmissible. A systematic review and meta-analysis estimated the average incubation period at about 7.6 days, with presymptomatic transmission documented in roughly a quarter to half of the paired cases investigators examined.¹ A prospective cohort study of high-risk contacts found viral DNA in specimens as early as four days before symptom onset, and in three of those cases, the virus was replication-competent, meaning it could infect cells and spread to others.² A separate study from Spain cultured infectious virus from individuals who had only mild, unrecognized symptoms or no symptoms at all before testing, reinforcing that presymptomatic and early-symptomatic phases can drive community transmission.³

This presymptomatic window creates a real public-health challenge. You can’t isolate based on a rash that hasn’t appeared yet, and most people won’t seek testing until something visible or painful develops. The practical implication is that close contacts of confirmed cases may have already been exposed days before anyone suspected infection.

How Long Skin Lesions Shed Live Virus

The skin rash is the most obvious source of contagion, and it typically lasts two to three weeks. Lesions progress through flat spots, raised bumps, fluid-filled blisters, and finally crusted-over scabs that eventually fall off. Crusting usually begins between seven and fourteen days after the rash first appears.⁴ In most public-health guidance, the person is considered contagious until all scabs have separated and new skin has formed underneath.

But there’s a gap between what PCR testing tells you and what viral culture tells you. PCR can detect fragments of viral genetic material for three to six weeks, well after the virus has stopped being able to infect anyone. A prospective study of patients in Spain found that replication-competent virus was only isolated from samples with high viral DNA levels, and the period of actual infectiousness was shorter than what PCR alone would suggest.⁵ A modeling study estimated that without treatment, skin lesions peaked in viral load around day 9 after infection and became undetectable by viral culture at a median of day 16, even though PCR didn’t turn negative until around day 29.⁶

In practical terms, this means a positive PCR test late in the course of illness doesn’t necessarily mean you’re still contagious. But because viral culture is slow, expensive, and not available in most clinical settings, PCR is what gets used, and the result often keeps people isolated longer than strictly necessary.

Shedding From Saliva, the Throat, and the Genital and Rectal Areas

Skin lesions aren’t the only source of infectious virus. Mpox can be detected in saliva, oropharyngeal swabs, anorectal swabs, urethral swabs, and semen, and each of these sites has a somewhat different timeline.

Saliva tends to carry surprisingly high viral loads. In one study of 25 patients with confirmed skin lesions, saliva had the highest viral loads of all the non-lesion specimen types tested, outpacing both blood plasma and throat swabs.⁷ A systematic review and meta-analysis estimated that the duration of viable viral isolation was about 14 days for saliva and 14 days for urethral specimens, while anorectal samples stayed positive for viable virus for about 19 days.⁸ By PCR, the shedding duration ran even longer: median shedding durations of about 19 days for saliva and 21 days for oropharyngeal swabs in another meta-analysis.⁹

The anorectal finding is worth underlining. Anorectal specimens had a particularly high yield of live, culturable virus compared to other body sites, and their estimated 19-day shedding duration was the longest of any site measured.⁸ This is significant because a large share of transmission during the 2022-2023 outbreak occurred through sexual contact, and anorectal shedding can continue for nearly three weeks after symptoms begin.

Semen is another confirmed source. Replication-competent virus has been found in seminal fluid, including from individuals who only engaged in receptive intercourse, ruling out simple contamination from genital lesions as the sole explanation.¹⁰ The full duration of semen shedding is less precisely characterized than shedding at other sites, but it adds another dimension to the question of when sexual activity is safe to resume.

When Immunosuppression Extends the Infectious Period

For people with healthy immune systems, the infectious window outlined above holds reasonably well. But in people with weakened immunity, all bets are off. The clearest evidence comes from people living with advanced HIV. A study from California comparing prolonged mpox infections to typical ones found that patients with prolonged courses were far more likely to have severely depleted immune cells: about 10% of those with prolonged infections had very low CD4 counts, compared with roughly 4% of those with standard courses. A much smaller share of prolonged-infection patients had their HIV under viral control, around 42%, compared to 72% in the non-prolonged group.¹¹

How long can this drag on? In extreme cases, months. A case report described a person with advanced HIV who had sight-threatening eye involvement with persistent mpox viral shedding for nearly five months, requiring a prolonged course of antiviral therapy.¹² A separate case series found replicating virus in ocular samples between day 31 and day 145 after skin lesion onset.¹³ These are uncommon scenarios, but they illustrate that the two-to-four-week contagious window assumed for immunocompetent patients can expand dramatically when the immune system can’t clear the virus.

Does Antiviral Treatment Shorten the Contagious Period?

Tecovirimat (brand name TPOXX) is the most-discussed antiviral for mpox, and the modeling data initially looked promising. When researchers simulated early treatment starting at symptom onset, the drug was predicted to shorten the time to undetectable culturable virus by about four to five days. Used as post-exposure prophylaxis, the benefit was more dramatic: it could reduce the duration of positive viral culture by seven to ten days and leave a substantial fraction of treated people never reaching infectious viral levels at all.⁶

The clinical trial results, however, were disappointing. A large randomized controlled trial published in the New England Journal of Medicine found that by day 29, about 83% of patients on tecovirimat and 84% on placebo had achieved clinical resolution, a difference that was effectively zero. There were no meaningful differences in pain reduction, complete lesion healing, or viral DNA clearance between the two groups.¹⁴ A companion virological analysis found that tecovirimat did not reduce the frequency of virus isolation from skin swabs, and a small number of patients developed treatment-emergent resistance mutations. Those who developed resistance had higher viral loads over time and markedly lower clinical resolution rates.¹⁵

The disconnect between the model and the trial likely comes down to timing. The model assumed treatment right at symptom onset, while real-world patients typically start treatment after the virus has already peaked. For now, tecovirimat is still used for severe cases and immunocompromised patients, but the evidence doesn’t support the idea that it reliably shortens how long a person is contagious.

Does Vaccination Change the Equation?

People vaccinated with JYNNEOS (the modified vaccinia Ankara vaccine) before exposure tend to get milder illness if they’re infected at all. A case-control study from California found that pre-exposure vaccination was associated with less severe disease, including fewer lesions that tended to stay localized and less frequent systemic symptoms like fever and body aches.¹⁶ That said, the vaccine doesn’t provide complete protection, and breakthrough infections do occur.¹⁷

Whether milder illness translates to a shorter contagious period is biologically plausible: fewer lesions and lower viral loads should mean less time shedding live virus. But the studies so far have focused on clinical severity rather than directly measuring shedding duration in vaccinated versus unvaccinated people. So while vaccination almost certainly helps on both fronts, the precise impact on contagiousness hasn’t been pinned down yet.

How Long Does the Virus Survive on Surfaces?

Mpox spreads primarily through direct contact, including skin-to-skin, sexual contact, and respiratory exposure during prolonged face-to-face interactions. But the virus can also survive on contaminated objects and surfaces, raising questions about laundry, shared bedding, and household cleaning.

An investigation of a household in Texas found extensive viral DNA on both porous (bedding, clothing) and nonporous (metal, plastic) surfaces after at least 15 days, and viable virus was successfully cultured from seven samples. The key finding: porous materials like bedding were far more likely to harbor live virus (60% of porous samples grew in culture) than hard surfaces like countertops (about 5%), though titers were low enough to suggest limited potential for indirect transmission.¹⁸

Laboratory studies paint a more detailed picture. On smooth nonporous surfaces at room temperature, viable virus was detected on glass and stainless steel for up to 5 days, on plastic for up to 3 days, and on porous materials like wood and cardboard for only 1 to 2 days.¹⁹ Temperature matters considerably: one study found that virus titers on clinical-setting materials dropped rapidly after about one day at room temperature, while at refrigerator temperatures (4°C), some materials harbored viable virus for up to three weeks.²⁰ That cold-temperature finding is relevant mostly for clinical waste and lab settings, not typical living spaces. At normal room temperatures, standard household cleaning and laundering of bedding and clothing should be enough to reduce the risk substantially.

A systematic review concluded that mpox was transmitted by direct physical contact in almost all documented cases, with very few confirmed instances of fomite transmission. The reviewers inferred that as long as all lesions are covered, direct contact is avoided, and a mask is worn, physical isolation of the patient may offer only marginal additional benefit beyond those precautions.²¹

How Isolation Guidelines Try to Match the Biology

Public health agencies generally tell people with mpox to isolate until all lesions have fully crusted over, the scabs have fallen off, and new skin has formed. A modeling study estimated that the average time from symptom onset to lesion clearance was about 25 days, and following this symptom-based rule left roughly a 9% chance of ending isolation while still infectious. The average patient was isolated about 12 days longer than strictly necessary based on viral culture data.²²

The same study compared three strategies: the current symptom-based rule, a fixed-duration rule (isolate for a set number of days), and a testing-based rule (end isolation when a test shows low enough viral load). A fixed-duration rule of about 22 days and a testing-based rule of about 20 days both performed better than the symptom-based approach, resulting in shorter isolation periods with similar or lower risk of premature release. People with slower-healing lesions needed considerably longer: up to 29 days under a fixed-duration rule to bring the risk of premature release below 5%.²²

The tension in all of this is straightforward. A conservative approach keeps people isolated for weeks longer than they’re actually shedding live virus, which has real costs to mental health, employment, and daily life. A looser approach risks sending people back into the world while they can still transmit. Testing-based release offers the best balance in theory, but it requires lab infrastructure and turnaround times that aren’t available everywhere.

Asymptomatic Infection and Silent Contagiousness

One of the harder aspects of mpox contagiousness to pin down is what happens in people who never develop obvious symptoms. A large screening study in Tokyo found that unrecognized or asymptomatic mpox among men who have sex with men was more common than previously thought, with a similar number of asymptomatic cases identified compared to symptomatic ones. Some of these asymptomatic individuals had PCR cycle threshold values below 30, which generally corresponds to higher viral loads and greater potential infectivity.²³

Whether asymptomatic cases shed enough virus for long enough to regularly transmit the infection remains an open question. The Japan study called for further investigation into the infectivity and shedding duration of these cases. The Spanish self-sampling study found that viable virus was only cultured from individuals who eventually reported at least some symptoms, though some of those symptoms were mild enough that the individuals hadn’t recognized them as mpox.³ The current picture suggests that truly asymptomatic cases are real but may be less likely to transmit than presymptomatic or mildly symptomatic ones. Still, the possibility of silent transmission complicates any clean answer about when contagiousness begins and ends.

Household Pets and the Risk of Cross-Species Spread

Given that mpox originated as a zoonotic disease in rodents, people with infections at home sometimes worry about transmitting the virus to their dogs or cats. A U.S. investigation examined pets in four households with confirmed human mpox cases and found viral DNA on swab samples from four dogs and one cat. But none of the animals had viable virus, and none showed antibodies against orthopoxviruses, suggesting that the DNA was surface contamination transferred from the infected humans rather than genuine animal infection.²⁴ The study found a strong correlation between human DNA and viral DNA on the animal swabs, reinforcing the contamination explanation. While the sample size was small and caution is still warranted, there was no evidence that common companion animals became infected or could serve as a secondary source of contagion in the household.

Ocular Shedding as a Late-Stage Concern

Eye involvement in mpox is uncommon but potentially serious, and it introduces one of the longest documented shedding timelines. A case series found replicating virus in ocular samples between day 31 and day 145 after the onset of skin lesions, long after the rash itself had resolved.¹³ These cases tend to occur in immunocompromised patients, and they highlight a scenario where the standard two-to-four-week contagious window doesn’t apply at all. Clinicians managing mpox patients with eye symptoms need to consider ongoing shedding well beyond the point where skin lesions have healed, and patients should be aware that their eyes may remain a source of virus even if the rest of their body appears to have cleared the infection.